margetuximab (MGAH 22) - MacroGenics
Margetuximab: "Margetuximab plus chemotherapy improved PFS (CBA: HR=0.76, P=0.033; Inv: HR=0.70, P=0.001), ORR, and CBR, compared with trastuzumab plus chemotherapy"; Breast cancer (Macrogenics) - Jun 5, 2019 - ASCO 2019: "Enhanced PFS benefit with margetuximab in exploratory subpopulation of low-affinity CD16A-158F carriers (HR=0.68, P=0.005)" 
P3 data
http://ir.macrogenics.com/static-files/75942c0b-c6df-49ac-b502-19fed2993d22
 
Jun 5, 2019
 
 
5676430b-ec90-4c9c-a1b2-773cdfcd3cd5.jpg

0f5f7acf-fc45-44c2-a56b-90af4ac53f4b.jpg